MedTrace Logo

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

NCT04921904 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-02-05

No results posted yet for this study

Summary

CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.

Conditions

  • Metastatic Esophageal Adenocarcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Abemaciclib

150mg dose administered orally twice daily every day

DRUG

Ramucirumab

8mg/kg iv every 2 weeks until evidence of disease

Sponsors & Collaborators

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • Ronan Kelly, MD · Charles A Sammons Cancer Center/Texas Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-11
Primary Completion
2024-12-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04921904 on ClinicalTrials.gov